Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Comtess

Comtess 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-087883 · Präparat HOS-083575

Entacapone binds to human albumin binding site II which also binds several other medicinal products, including diazepam and ibuprofen. Clinical interaction studies with diazepam and non- steroidal anti-inflammatory medicinal products have not been carried out. According to in vitro studies, significant displacement is not anticipated at therapeutic concentrations of the medicinal products.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) diazepam (HOS-085904)

Wechselwirkungen · Comtan

Comtan 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5

HOS-087907 · Präparat HOS-083583

Entacapone binds to human albumin binding site II which also binds several other medicinal products, including diazepam and ibuprofen. Clinical interaction studies with diazepam and non- steroidal anti-inflammatory medicinal products have not been carried out. According to in vitro studies, significant displacement is not anticipated at therapeutic concentrations of the medicinal products.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) diazepam (HOS-085904)

Wechselwirkungen · Evista

Evista 60 mg film coated tablets · Abschnitt 4.5 · PDF-Seite 4

HOS-088376 · Präparat HOS-083635

The influence of concomitant medication on raloxifene plasma concentrations was evaluated in the prevention and treatment trials. Frequently co-administered medicinal products included: paracetamol, non-steroidal anti-inflammatory drugs (such as acetylsalicylic acid, ibuprofen, and naproxen), oral antibiotics, H1 antagonists, H2 antagonists, and benzodiazepines. No clinically relevant effects of the co-administration of the agents on raloxifene plasma concentrations were identified.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) naproxen (HOS-087936)

Wechselwirkungen · Vfend

VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 16–17

HOS-109484 · Präparat HOS-093201

16 Non-steroidal selective mineralocorticoid receptor (MR) antagonists Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax  20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-  100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax  114% needed. Diclofenac AUC0-  78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax  1.7-fold other long-acting opiates Oxycodone AUC0-  3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax  31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUC  47% reactions and toxicity related to S-methadone Cmax  65% methadone, including QTc S-methadone AUC  103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-  6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-  1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax  36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC  61% related to oral contraceptives, in inhibitor] Norethisterone Cmax  15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUC  53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax  14% Voriconazole AUC  46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)

Wechselwirkungen · Vfend

VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 48–49

HOS-109554 · Präparat HOS-093201

48 Non-steroidal selective mineralocorticoid receptor (MR) antagonists Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax  20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-  100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax  114% needed. Diclofenac AUC0-  78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax  1.7-fold other long-acting opiates Oxycodone AUC0-  3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax  31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUC  47% reactions and toxicity related to S-methadone Cmax  65% methadone, including QTc S-methadone AUC  103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-  6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-  1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax  36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC  61% related to oral contraceptives, in inhibitor] Norethisterone Cmax  15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUC  53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax  14% Voriconazole AUC  46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)

Wechselwirkungen · Vfend

VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 80–81

HOS-109619 · Präparat HOS-093201

80 Non-steroidal selective mineralocorticoid receptor (MR) antagonists Finerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of finerenone. Eplerenone Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of eplerenone. Non-steroidal anti-inflammatory drugs (NSAIDs) [CYP2C9 substrates] Frequent monitoring for adverse S-Ibuprofen Cmax  20% reactions and toxicity related to Ibuprofen (400 mg single dose) S-Ibuprofen AUC0-  100% NSAIDs is recommended. Dose reduction of NSAIDs may be Diclofenac (50 mg single dose) Diclofenac Cmax  114% needed. Diclofenac AUC0-  78% Opioids Long-Acting Opiates In an independent published study, Dose reduction in oxycodone and [CYP3A4 substrates] Oxycodone Cmax  1.7-fold other long-acting opiates Oxycodone AUC0-  3.6-fold metabolised by CYP3A4 Oxycodone (10 mg single (e.g., hydrocodone) should be dose) considered. Frequent monitoring for opiate-associated adverse reactions may be necessary. Methadone (32-100 mg QD) R-methadone (active) Cmax  31% Frequent monitoring for adverse [CYP3A4 substrate] R-methadone (active) AUC  47% reactions and toxicity related to S-methadone Cmax  65% methadone, including QTc S-methadone AUC  103% prolongation, is recommended. Dose reduction of methadone may be needed. Short-acting Opiates Dose reduction of alfentanil, [CYP3A4 substrates] fentanyl and other short-acting opiates similar in structure to Alfentanil (20 μg/kg single In an independent published study, alfentanil and metabolised by dose, with concomitant Alfentanil AUC0-  6-fold CYP3A4 (e.g., sufentanil) should naloxone) be considered. Extended and frequent monitoring for Fentanyl (5 g/kg single dose) In an independent published study, respiratory depression and other Fentanyl AUC0-  1.34-fold opiate-associated adverse reactions is recommended. Opioid receptor antagonists Naloxegol Although not studied, voriconazole Contraindicated (see section [CYP3A4 substrate] is likely to significantly increase 4.3) the plasma concentrations of naloxegol. Oral contraceptives Oral Contraceptives* Ethinylestradiol Cmax  36% Monitoring for adverse reactions [CYP3A4 substrate; CYP2C19 Ethinylestradiol AUC  61% related to oral contraceptives, in inhibitor] Norethisterone Cmax  15% addition to those for Norethisterone/ethinylestradiol Norethisterone AUC  53% voriconazole, is recommended. (1 mg/0.035 mg QD) Voriconazole Cmax  14% Voriconazole AUC  46%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfentanil (HOS-109375) diclofenac (HOS-085903) ibuprofen (HOS-087884) methadone (HOS-086198) eplerenone (HOS-089050) oxycodone (HOS-109487) finerenone (HOS-109430) naloxegol (HOS-109428) hydrocodone (HOS-109488) naloxone (HOS-109490) fentanyl (HOS-086196) sufentanil (HOS-109489)

Wechselwirkungen · Stalevo

Stalevo 50 mg/12.5 mg/200 mg film-coated tablets Stalevo 75 mg/18.75 mg/200 mg film-coated tablets Stalevo 100 mg/25 mg/200 mg film-coated tablets Stalevo 125 mg/31.25 mg/200 mg film-coated tablets Stalevo 150 mg/37.5 mg/200 mg film-coated tablets Stalevo 175 mg/43.75 mg/200 mg film-coated tablets Stalevo 200 mg/50 mg/200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7

HOS-112325 · Präparat HOS-093651

In vitro data: Entacapone binds to human albumin binding site II which also binds several other medicinal products, including diazepam and ibuprofen. According to in vitro studies, significant displacement is not anticipated at therapeutic concentrations of the medicinal products. Accordingly, to date there has been no indication of such interactions.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) diazepam (HOS-085904)

Gegenanzeigen · Pedea

Pedea 5 mg/ml solution for injection · Abschnitt 4.3 · PDF-Seite 3

HOS-112954 · Präparat HOS-093805

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1; - Life-threatening infection; - Active bleeding, especially intracranial or gastrointestinal haemorrhage; - Thrombocytopenia or coagulation defects; - Significant impairment of renal function; - Congenital heart disease in which patency of the ductus arteriosus is necessary for satisfactory pulmonary or systemic blood flow (e.g. pulmonary atresia, severe tetralogy of Fallot, severe coarctation of the aorta); - Known or suspected necrotising enterocolitis;

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Pedea

Pedea 5 mg/ml solution for injection · Abschnitt 4.5 · PDF-Seite 4

HOS-112955 · Präparat HOS-093805

The concomitant use of Pedea with the following medicinal products is not recommended: - diuretics: ibuprofen may reduce the effect of diuretics; diuretics can increase the risk of nephrotoxicity of NSAIDs in dehydrated patients. - anticoagulants: ibuprofen may increase the effect of anticoagulants and enhance the risk of bleeding. - corticosteroids: ibuprofen may increase the risk of gastrointestinal bleeding. - nitric oxide: since both medicinal products inhibit platelet function, their combination may in theory increase the risk of bleeding. - other NSAIDs: the concomitant use of more than one NSAID should be avoided because of the increased risk of adverse reactions. - aminoglycosides: since ibuprofen may decrease the clearance of aminoglycosides, their co- administration may increase the risk of nephrotoxicity and ototoxicity (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nitric oxide (HOS-088773)

Nebenwirkungen · Pedea

Pedea 5 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 4

HOS-112956 · Präparat HOS-093805

Data are currently available on approximately 1,000 preterm newborn from both the literature concerning ibuprofen and clinical trials with Pedea. Causality of adverse events reported in the preterm newborn is difficult to assess since they may be related to the haemodynamic consequences of the patent ductus arteriosus as well as to direct effects of ibuprofen.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Pedea

Pedea 5 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 4

HOS-112957 · Präparat HOS-093805

Reported adverse reactions are listed below, by system organ class and by frequency. Frequencies are defined as: very common (≥ 1/10), common (≥1/100, <1/10) and uncommon (≥1/1,000, <1/100). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Pedea

Pedea 5 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 4

HOS-112958 · Präparat HOS-093805

Blood and lymphatic system disorders Very common: Thrombocytopenia, Neutropenia Nervous system disorders Common: Intraventricular haemorrhage, Periventricular leukomalacia Respiratory, thoracic and mediastinal Very common: Bronchopulmonary dysplasia* disorders Common: Pulmonary haemorrhage Uncommon: Hypoxemia* Gastrointestinal disorders Common: Necrotizing enterocolitis, Intestinal perforation Uncommon: Gastrointestinal haemorrhage Unknown: Gastric perforation Renal and urinary disorders Common: Oliguria, Fluid retention, Haematuria Uncommon: Acute renal failure Investigations Very Common: Blood creatinine increased, Blood sodium decreased Skin and subcutaneous tissue disorders Not known: Acute generalised exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Pedea

Pedea 5 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 4–5

HOS-112959 · Präparat HOS-093805

4 * see below

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Pedea

Pedea 5 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 5

HOS-112960 · Präparat HOS-093805

In a clinical curative trial involving 175 preterm newborn infants less than 35 weeks of gestational age, the incidence of bronchopulmonary dysplasia at 36 weeks post-conceptional age was 13/81 (16%) for indomethacin versus 23/94 (24%) for ibuprofen.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Pedea

Pedea 5 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 5

HOS-112961 · Präparat HOS-093805

In a clinical trial where Pedea was administered prophylactically during the first 6 hours of life, severe hypoxemia with pulmonary hypertension was reported in 3 newborn infants less than 28 weeks of gestational age. This occurred within one hour of the first infusion and was reversed within 30 minutes after the inhalation of nitric oxide. There have also been post-marketing reports of pulmonary hypertension where Pedea was administered to premature neonates in the therapeutic setting.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Nebenwirkungen · Pedea

Pedea 5 mg/ml solution for injection · Abschnitt 4.8 · PDF-Seite 5

HOS-112962 · Präparat HOS-093805

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Wechselwirkungen · Alimta

ALIMTA 100 mg powder for concentrate for solution for infusion ALIMTA 500 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7

HOS-113238 · Präparat HOS-093893

In patients with normal renal function (creatinine clearance > 80 ml/min), high doses of non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen > 1600 mg/day) and acetylsalicylic acid at higher dose (> 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse reactions. Therefore, caution should be made when administering higher doses of NSAIDs or acetylsalicylic acid, concurrently with pemetrexed to patients with normal function (creatinine clearance > 80 ml/min).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) creatinine (HOS-086273)

Wechselwirkungen · Alimta

ALIMTA 100 mg powder for concentrate for solution for infusion ALIMTA 500 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 7

HOS-113239 · Präparat HOS-093893

In patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 ml/min), the concomitant administration of pemetrexed with NSAIDs (e.g. ibuprofen) or acetylsalicylic acid at higher dose should be avoided for 2 days before, on the day of, and 2 days following pemetrexed administration (see section 4.4).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884) creatinine (HOS-086273)

Wechselwirkungen · Xyrem

Xyrem 500 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 7

HOS-113665 · Präparat HOS-093953

Ibuprofen Drug interaction studies in healthy adults demonstrated no pharmacokinetic interactions between sodium oxybate and ibuprofen.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ibuprofen (HOS-087884)

Wechselwirkungen · Advagraf

Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10

HOS-116792 · Präparat HOS-094481

Medicinal products which have effects on tacrolimus Drug/Substance Class or Drug interaction effect Recommendations concerning Name co-administration Grapefruit or grapefruit juice May increase tacrolimus whole Avoid grapefruit or grapefruit blood trough concentrations and juice. increase the risk of serious adverse reactions (e.g., neurotoxicity, QT prolongation) [see section 4.4]. Ciclosporin May increase tacrolimus whole The simultaneous use of blood trough concentrations. In ciclosporin and tacrolimus addition, synergistic/additive should be avoided [see nephrotoxic effects can occur. section 4.4]. Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus nephrotoxic or neurotoxic neurotoxic effects of tacrolimus. with drugs known to have effects: nephrotoxic effects should be aminoglycosides, gyrase avoided. When co- inhibitors, vancomycin, administration cannot be sulfamethoxazole + avoided, monitor renal trimethoprim, NSAIDs, function and other side effects ganciclovir, acyclovir, and adjust tacrolimus dose if amphotericin B, ibuprofen, needed. cidofovir, foscarnet

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ibuprofen (HOS-087884) amphotericin B (HOS-109312) trimethoprim (HOS-085184) cidofovir (HOS-110482) grapefruit juice (HOS-088787) vancomycin (HOS-110486) ganciclovir (HOS-085194) acyclovir (HOS-088527)